AmplifyBio builds on the T-cell immunology expertise of its South San Francisco-based team, adding technology platforms and capabilities in single-cell analysis and product assessment in the context of
/PRNewswire/ AmplifyBio, a contract research organization (CRO) focused on accelerating innovation across pharmaceutical modalities; today announced the.
09 15 22 -- 5 Steps To Avoid Mismanaging Biopharma Grant Funds pharmaceuticalonline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmaceuticalonline.com Daily Mail and Mail on Sunday newspapers.
Read Time:
Cobra Biologics, the gene therapy division of the Cognate BioServicesâ group, has today announced a multi-phase augmentation of its plasmid DNA services as a continuation of its Gene Therapy servicesâ expansion project for viral vectors and plasmid DNA. This includes a four-fold increase in HQ (High Quality) DNA manufacturing capacity alongside new clinical and commercial GMP DNA facilities at its European facilities. The HQ plasmid manufacturing service provides a rapid six-week delivery time for the clinical manufacture of immuno-oncology therapies, for example products utilizing AAV, lentiviral vector and CRISPR products.
After its acquisition of Cobra Biologics in January 2020, Cognate has positioned itself as a global provider of end-to-end capabilities in the development and manufacturing of cell & gene therapy products. This expansion is in direct response to the great demand of commercial capacity within the biologics industry.